Climb Bio, Inc.CLYM
What Climb Bio, Inc. does.
We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for patients living with immune-mediated diseases. We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development pathways, and the potential to address multiple indications.
We are developing our product candidates for multiple immune-mediated diseases, as summarized in the pipeline figure below.
We acquired the rights to our product candidates through license and asset purchase agreements. We have worldwide rights to develop and commercialize budoprutug for all indications, except for oncology. We have rights to develop and commercialize CLYM116 for all indications worldwide outside of mainland China, Hong Kong, Macau, and Taiwan, which we refer to as Greater China.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$20.7M | -$47.5M | -$45.2M | -$35.1M | -$73.9M | -$59.9M |
| Free cash flow | — | — | — | -$20.6M | -$15.6M | -$54.5M |
More on CLYM.
- Climb Bio, Inc. summary
- Climb Bio, Inc. financial statements
- Climb Bio, Inc. key metrics
- Climb Bio, Inc. health scores and style box
- Climb Bio, Inc. earnings
- Climb Bio, Inc. dividends
- Climb Bio, Inc. valuation
- Climb Bio, Inc. ownership and insiders
- Climb Bio, Inc. peers
Figures from Climb Bio, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.